National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

alvimopan
A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opiod-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Entereg
Code names:ADL8-2698
LY-246376



Previous:alum adjuvant, ALVAC(2) melanoma multi-antigen therapeutic vaccine, ALVAC-hB7.1, ALVAC-MART-1 vaccine, alvespimycin hydrochloride
Next:alvocidib, amantadine hydrochloride, Ambien, AmBisome, Ambochlorin

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov